This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jaime L. Mayoral, MD; Cynthia M. Loeffler, MD; Carlos G. Fasola, MD; Marie A. Kramer, RN; William J. Orrom, MD; Arthur J. Matas, MD; John S. Najarian, MD; David L. Dunn, MD, PhD

Arch Surg. 1991;126(2):202-206.

Abstract
• Infection due to cytomegalovirus is a substantial cause of morbidity and mortality in immunocompromised patients. In particular, cytomegalovirus infection has been associated with a significant detrimental effect on patient and allograft survival after solid-organ transplantation. We are evaluating a new antiviral agent, ganciclovir 9-[1,3-dihydroxy-2-2 propoxymethyl] guanine (DHPG), used in solid-organ transplant recipients who developed life-threatening cytomegalovirus infections. Between March 1, 1987, and June 30, 1989, we treated 93 solid-organ transplant patients who developed tissue-invasive cytomegalovirus disease. From this group of patients we have identified 14 patients with primary gastrointestinal cytomegalovirus disease who received treatment with DHPG. Tissue diagnosis was made by endoscopy of the upper gastrointestinal tract (11 patients) or colonoscopy (three patients). Invasive cytomegalovirus disease was identified prior to severe complications of the gastrointestinal tract in all but one patient, who suffered colonic perforation prior to treatment with DHPG and subsequently died of bacterial sepsis. While 13 of the 14 patients improved after treatment with DHPG, four patients required additional treatments for recurrent cytomegalovirus disease and recovered. No DHPG toxicity was observed. We believe treatment with DHPG is indicated in this patient population, but that further studies are indicated to fully define the impact of this recommendation on both patient and allograft survival after solid-organ transplantation.

(Arch Surg. 1991;126:202-206)

Author Affiliations
From The Department of Surgery, Division of Surgical Infectious Diseases, University of Minnesota, Minneapolis.

Footnotes
Accepted for publication October 28, 1990.

Read before the Tenth Anniversary Meeting of the Surgical Infection Society, Cincinnati, Ohio, June 14, 1990.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal
Davies et al.
Nephrol Dial Transplant 2007;22:2440-2448.
ABSTRACT | FULL TEXT  

Diagnosis and Treatment of Bowel Perforation Following Pediatric Orthotopic Liver Transplantation
Shaked et al.
Arch Surg 1993;128:994-999.
ABSTRACT  

Treatment of Recurrent Cytomegalovirus Disease in Patients Receiving Solid Organ Transplants
Sawyer et al.
Arch Surg 1993;128:165-170.
ABSTRACT